A delegation from Chongqing Yufu Holding Group and Chongqing Machinery & Electrical Group paid a visit to Hemos Bioscience for inspection and exchange.

July 10, Chongqing Yufu Holding Group Co., Ltd. (hereinafter referred to as “Yufu Holding Group”) and Chongqing Machinery & Electronics Holding (Group) Co., Ltd. (hereinafter referred to as “Machinery & Electronics Group”) A delegation paid a visit to Hemos Bioscience for an inspection and exchange, gaining first-hand insights into the company’s R&D capabilities, industrialization progress, and market strategy. The parties then held a symposium to discuss ways to deepen industrial collaboration and expand avenues for cooperation.

During this inspection and exchange, a delegation from Yufu Holding Group and the Machinery and Electrical Equipment Group conducted an on-site visit to… Hemos Bioscience At the R&D and production base, we gained an in-depth understanding of the company’s technological breakthroughs, product portfolio, and industrialization achievements in the field of Recombinant Keratin. We highly commended its demonstrated capabilities in independent innovation and its strong technological barriers, noting that its technological roadmap is clear, its market prospects are broad, and it has the potential to become a leading enterprise in its niche segment.

At the symposium, the three parties engaged in substantive discussions centered on a collaborative model integrating “capital, industry, and technology.” As the city-level state-owned capital operation platform, Yufu Holding Group places particular emphasis on investment deployment in strategic emerging industries, and will actively leverage its role as a capital-driving force to support the growth and expansion of high-quality local biomanufacturing enterprises. Chongqing Machinery & Electronics Group, leveraging its subsidiaries… Dengkang Oral Care Building on the strategic raw-material partnership already established with Hemos, discussions explored multi-dimensional, in-depth collaboration pathways—ranging from ensuring large-scale raw-material supply and upgrading production automation to jointly developing end products. Meanwhile, Hemos Bioscience provided a detailed overview of the company’s strategic plan, its R&D pipeline, and its specific needs regarding industry resources.

This fact-finding and exchange visit has strengthened mutual trust and consensus between the city’s key state-owned enterprises and local innovative biotechnology firms. All three parties agreed to establish a regular communication mechanism, actively explore synergies across multiple dimensions—including capital, industry, and technology—so as to share resources, leverage complementary strengths, and achieve mutually beneficial outcomes. They also pledged to ensure effective alignment of their respective resources, thereby laying a solid foundation for deeper cooperation in the next phase.

Hemos Bioscience will take this exchange as a starting point, continuously strengthen its technological foundation and expand production capacity, actively leverage the capital, industrial, and market advantages of the two major groups, explore diverse application scenarios in the field of bio-new materials, contribute to the highquality development of Chongqing’s biopharmaceutical and advanced materials industry clusters, and help build a modernized Chongqing.